Is TB-500 Legal in Washington State? How to Access It Legally

What Exactly Is TB-500?

TB-500 is a 43-amino-acid synthetic peptide derived from thymosin beta-4 (Tβ4), a naturally occurring protein found in nearly all human and animal cells. Researchers first isolated thymosin beta-4 from bovine thymus tissue in the 1980s. The peptide appears to regulate actin polymerization, support angiogenesis, and modulate inflammatory signaling pathways. Studies in rodent wound-healing models showed accelerated dermal repair after Tβ4 administration, which drove early clinical interest.

TB-500 vs. Full-Length Thymosin Beta-4

The distinction matters legally. Full-length thymosin beta-4 is a 43-amino-acid protein. TB-500 specifically refers to the fragment Ac-SDKP (or a closely related synthetic analog), though the term is used loosely in commercial markets. The FDA evaluates each peptide sequence individually, so the regulatory status of "TB-500" may differ from full-length Tβ4 depending on how a compounding pharmacy formulates the product.

Mechanism of Action at a Glance

Thymosin beta-4 sequesters G-actin, reducing the pool available for filament formation. This action modulates cell migration and tissue remodeling. A 2010 study in the Journal of Cell Science demonstrated that Tβ4 peptides promote corneal epithelial cell migration at concentrations as low as 1 nanomolar. No large randomized controlled trial has established a standard therapeutic dose in humans for any indication outside of a sponsored IND program.

Current Human Research Status

RegeneRx Biopharmaceuticals conducted Phase II trials of RGN-352 (a full-length Tβ4 formulation) for cardiac repair after acute myocardial infarction. The RGN-352 Phase II trial enrolled 91 patients and showed a numerical but not statistically significant improvement in left ventricular ejection fraction (P<0.30). No Phase III trial has been completed. A separate Phase II program for dry eye disease (RGN-259) reached completion; results are registered at ClinicalTrials.gov NCT02597699. Neither program produced an FDA-approved product as of mid-2025.

Federal Legal Framework: FDA Rules That Apply Nationwide

Understanding TB-500's federal status is the first step, because federal law overrides any Washington State policy wherever the two conflict.

New Drug and IND Requirements

Any peptide intended for therapeutic use in humans is subject to the Federal Food, Drug, and Cosmetic Act (FD&C Act). Under 21 U.S.C. § 321(g), a substance qualifies as a "drug" when it is intended to diagnose, cure, treat, or prevent disease. TB-500 sold with therapeutic claims meets that definition. Without an approved New Drug Application (NDA) or an active Investigational New Drug (IND) exemption, selling or distributing TB-500 for human therapeutic use violates federal law. The FDA's drug approval process requires demonstrated safety and efficacy before commercial distribution.

Compounding Under 503A and 503B

Congress created two legal compounding pathways in the Drug Quality and Security Act of 2013. A 503A pharmacy compounds drugs for individual patients based on a valid prescription from a licensed practitioner. A 503B outsourcing facility compounds larger batches for healthcare providers without patient-specific prescriptions but must register with the FDA and comply with current Good Manufacturing Practice (cGMP) standards.

Both pathways restrict which bulk drug substances can be used. The FDA maintains a list of bulk substances evaluated for 503A use. Thymosin beta-4 was placed on the FDA's Category 2 bulks list in 2023. Category 2 means the FDA has reviewed the substance and determined it does NOT meet the criteria for inclusion on the 503A bulk substances list. This effectively restricts 503A pharmacies from compounding thymosin beta-4 unless the FDA reverses that decision.

What Category 2 Means in Practice

The FDA's 503A bulks guidance specifies that a bulk substance may be used in 503A compounding only if it appears on a final or interim 503A bulks list or qualifies under one of the FD&C Act's named-substance provisions. A Category 2 placement signals that compounding with that substance is not permitted under 503A. Pharmacies and prescribers who proceed face FDA enforcement action. The FDA's 2023 proposed rule on bulk substances formalized this position.

Research Chemical Sales: A Separate Legal Channel With Serious Limits

Some vendors sell TB-500 labeled "for research use only, not for human use." This channel exploits a narrow exemption: chemical suppliers may sell substances for legitimate in-vitro or animal research without FDA drug approval. The exemption has real limits, however. The FDA's guidance on research chemicals makes clear that products sold with implied or explicit human-use intent do not qualify for the research-use exemption. The agency has issued Warning Letters to multiple peptide vendors for exactly this violation. Purchasing from these vendors carries personal legal risk and zero quality assurance.

Washington State Legal Framework

Washington State does not create a separate approval pathway for unapproved peptides. State law layers on top of federal law and, in some areas, adds stricter requirements.

Washington State Pharmacy Commission

The Washington State Pharmacy Commission, operating under the Washington State Department of Health, licenses pharmacists and pharmacy facilities in the state. In-state 503A compounding pharmacies must comply with both Washington Administrative Code (WAC) Chapter 246-878 and federal 503A requirements. Out-of-state 503B outsourcing facilities that ship product into Washington must hold a Washington non-resident pharmacy license.

Washington Medical Practice Act

Washington's Uniform Disciplinary Act (RCW 18.130) governs licensed health professionals. A physician, physician assistant, or advanced registered nurse practitioner may prescribe an approved or compounded drug within the scope of their license and within the standard of care. Prescribing a compounded peptide that does not appear on the FDA's approved 503A bulks list exposes a prescriber to potential professional discipline if the prescription falls outside accepted practice. No Washington State statute specifically names TB-500 as a controlled or prohibited substance, but the absence of a specific prohibition does not create permission.

Controlled Substance Scheduling in Washington

Washington's Uniform Controlled Substances Act (RCW 69.50) lists Schedule I through V substances. Thymosin beta-4 and TB-500 do not appear on any Washington or federal controlled substance schedule as of mid-2025. This means possession for personal use does not constitute a controlled-substance offense under state law. Federal drug law is a separate matter, and the FD&C Act's misbranding and adulteration provisions can still apply.

The Four Legal Access Scenarios in Washington

Patients and clinicians in Washington encounter four realistic scenarios. Each has a different legal profile.

Scenario 1: Prescription From a Washington Physician, Compounded by a Licensed 503A Pharmacy Using an Approved Bulk

This was a viable path before the 2023 Category 2 determination. If the FDA reverses its Category 2 decision or adds Tβ4 to the 503A bulks list, this pathway reopens. A patient obtains a prescription, a licensed Washington 503A pharmacy sources the bulk substance from an FDA-registered bulk manufacturer, and the pharmacy compounds a patient-specific preparation. Quality, sterility, and potency are the pharmacy's legal responsibility under USP <797> standards for sterile compounding.

Scenario 2: Prescription Using a 503B Outsourcing Facility

503B outsourcing facilities operate under cGMP and may compound substances that are not on the 503A bulks list under certain circumstances, though they face parallel FDA scrutiny. If a 503B facility has completed the required FDA review for a specific peptide formulation and received no objection, a prescriber may be able to order product. Patients should confirm with their prescriber and the specific facility whether thymosin beta-4 products are currently being dispensed lawfully from a registered 503B source. The FDA's list of registered outsourcing facilities is publicly searchable.

Scenario 3: Enrollment in a Clinical Trial With an Active IND

If a sponsor holds an active IND for a thymosin beta-4 study, enrolled participants may receive the investigational drug legally. The FDA's IND process requires institutional review board oversight and informed consent. Washington-based academic medical centers such as the University of Washington Medicine may host relevant oncology, wound healing, or cardiac trials. Patients can search ClinicalTrials.gov for active Tβ4 or TB-500 trials enrolling in Washington.

Scenario 4: Purchasing From a "Research Chemical" Vendor

No legal protection exists for a Washington resident who buys TB-500 from an online research-chemical vendor and self-administers it. The substance may be mislabeled, contaminated, or incorrectly dosed. Product purity in the research-chemical market is unreliable: a 2021 analysis published in Drug Testing and Analysis found that peptide products purchased from online vendors frequently contained incorrect concentrations or undisclosed adulterants. Self-administration without medical oversight creates both legal exposure and genuine health risk.

Safety and Risk Profile of TB-500

No completed Phase III trial has established the safety profile of TB-500 or thymosin beta-4 in large human populations. Extrapolating from animal studies to human dosing is scientifically unreliable.

Reported Adverse Effects in Human Studies

The Phase II cardiac trial of RGN-352 reported adverse events similar to placebo, with the most common being injection-site reactions in 8% of active-arm participants. That trial enrolled only 91 subjects, making rare adverse events difficult to detect. STAT-ATED, a Phase II dry eye trial of RGN-259 (ophthalmic Tβ4) showed a favorable ocular safety profile in 72 patients over 28 days. Neither dataset supports safety conclusions for systemic subcutaneous TB-500 at the doses sold commercially.

Anti-Doping Status

The World Anti-Doping Agency (WADA) lists thymosin beta-4 on its Prohibited List under peptide hormones, growth factors, and related substances. Athletes subject to WADA rules, including most Olympic sport competitors and many professional leagues governed by USADA, face sanctions for TB-500 use regardless of how they obtained it. USADA's 2023 annual report documented sanctions in cases involving peptide use.

Drug Interaction Considerations

Thymosin beta-4 has theoretical interactions with anticoagulant therapy. Because Tβ4 promotes angiogenesis through upregulation of vascular endothelial growth factor (VEGF), concurrent use with anti-VEGF agents used in oncology (such as bevacizumab) may produce opposing pharmacodynamic effects. The NCI drug interaction database does not yet include specific Tβ4 entries, reflecting the absence of approved human pharmacokinetic data.

How Washington Patients Can Start the Conversation With a Prescriber

Patients interested in TB-500 for wound healing, anti-inflammatory effects, or tissue repair should approach the conversation with specific information.

What to Bring to the Appointment

Bring the published trial data, specifically the RegeneRx Phase II cardiac data and the dry eye trial results. Ask your prescriber to document the clinical rationale in the medical record. Discuss whether an IND-covered trial or an evidence-based alternative such as platelet-rich plasma (PRP) therapy, which does have published supporting data in systematic reviews on wound healing, might better serve the treatment goal.

Telehealth Prescribing in Washington

Washington State permits telehealth prescribing under RCW 70.41.020 provided a valid patient-provider relationship exists. A telehealth consultation with a Washington-licensed physician who specializes in peptide or regenerative medicine satisfies the prescription requirement, though the compounding pharmacy constraints described above still apply. The prescriber must be licensed in Washington for the prescription to be valid in this state.

Questions to Ask Any Compounding Pharmacy

Before agreeing to a compounded peptide preparation, ask the pharmacy four things: Is the bulk substance supplier FDA-registered? Does the pharmacy hold current USP <797> accreditation for sterile compounding? Has the specific formulation been tested for potency and sterility by a third-party laboratory? Does the pharmacy operate under 503A or 503B? Acceptable answers are specific and documentable. A pharmacy unable to answer these questions is not a suitable source.

Alternatives With Established Legal and Clinical Status in Washington

Patients seeking tissue repair or anti-inflammatory effects through peptide therapy have legally clearer options.

BPC-157, another peptide of interest, currently sits on the FDA's Category 1 bulks list as "under evaluation," which is a more permissive interim status than thymosin beta-4's Category 2 determination. Pentadecapeptide BPC-157 animal data published in the Journal of Physiology and Pharmacology suggests healing effects in gastrointestinal tissue, though human trial evidence is sparse. Platelet-rich plasma (PRP) is another option: it is regulated as a human cells, tissues, and cellular and tissue-based product (HCT/P) under 21 CFR Part 1271 and administered in office by a licensed provider without the compounding pharmacy restrictions that affect TB-500. Low-level laser therapy and hyperbaric oxygen therapy both carry specific CPT codes and established reimbursement pathways for wound-healing indications in Washington.